Canada markets closed

Medtronic plc (MDT)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
102.98-1.37 (-1.31%)
At close: 4:00PM EDT

102.98 0.00 (0.00%)
After hours: 4:46PM EDT

Sign in to post a message.
  • L
    LA
    If MDT gos under $100 again. HUGE BUY!
  • B
    Bill mddb
    Nice to see a bid in for MDT. I have been impressed with core profitability which has allowed MDT to post positive earnings with revenue and gross margins depressed. MDT's tried and seasoned products have higher than average margin and cover a lot of SG&A. So that's a clarified fundamental that can now be attributed to MDT's established product portfolio. Mgt & BOD seem to have managed well given no reduction in ongoing R&D, the extra $337 mil of diabetes R&D added from the Blackstone Life Sciences fund, and the 7% dividend increase was a positive signal to look past C-19. MDT is a Buffet stock. Even if US tax rates go up it's on about 53% of revenue.
  • N
    No
    Volume is modest. Expecting price flatening next couple of days as EE’s exercise options. Otherwise, slow and steady upward momentum. MDT is still in the top quadrant for its sector, a tool used by brokerage houses. Im playing the momentum.
  • C
    Carl
    Nice earnings
  • B
    Bill mddb
    Medtronic MDT-NYSE
    Buy -- Price $100.05 on Aug. 7
    by Edward Jones

    Medtronic is one of the most diversified medical-technology companies in the world, specializing in cardiac and vascular devices, restorative therapies, diabetes devices, and minimally invasive therapies. Its innovative new products in robotic surgery, diabetes, and pacemakers, along with its strong brand reputation, should support solid long-term growth. Medtronic has a market-leading position in most areas that it operates in. While pricing pressure is a risk in the medical-device industry, we believe that Medtronic’s ability to continue to develop innovations will more than offset this risk.
  • b
    bills
    My biggest complaint about MDT is that the dividend yield keeps dropping. 😁
  • B
    Bill mddb
    The FDA approves Medtronic's (NYSE:MDT) MiniMed 770G System, a hybrid closed-loop diabetes management device, for children ages 2 - 6 with type 1 diabetes, the first such system available in the U.S.
    The FDA approves Medtronic's (NYSE:MDT) MiniMed 770G System, a hybrid closed-loop diabetes management device, for children ages 2 - 6 with type 1 diabetes, the first such system available in the U.S.
    seekingalpha.com
  • B
    Bill mddb
    Nice 5% run for the stock, albeit on low trading volumes so far. Up on an acquisition announcement is good to see. It's a question of time until MDT gets back on track at the $120 level of earlier this year. Won't be a straight line -- may be until Q3 (Nov, Dec, Jan) before full revenue is flowing, assuming C-19 is under control.
  • K
    Kat
    Amazing New About Pump for Children. Buy Ratings. Why IS this a Standstill? 130!
  • N
    No
    Im bullish, here’s why. MDT offers a complete suite of products and services for the entire medical ecosystem. COVID-19 cut off core revenue streams by forcing hospitals to focus on treating C-19, stopping elective procedures, stopping clinical research, a profit center. The improved treatment of C-19 allows hospitals to allow elective procedures and restart clinical research. The future is a slow and unsexy return to higer revenues and margins. MDT is sitting on $$$ reserves that is used for acquisition as we have seen, leading to stronger future growth.
  • Y
    Yahoo Finance Insights
    Medtronic is up 4.96% to 105.10
  • B
    Bill mddb
    The mention I saw about MDT was one of the CNBC fast money guys say he liked it to recover post Covid and be a good bet based on demographics.
  • B
    Bill mddb
    Medtronic (NYSE:MDT) announces the FDA nod for its InterStim Micro sacral nerve modulator (SNM) for the treatment of overactive bladder, fecal incontinence and non-obstructive urinary retention.
    Medtronic (NYSE:MDT) announces the FDA nod for its InterStim Micro sacral nerve modulator (SNM) for the treatment of overactive bladder, fecal incontinence and non-obstructive urinary retention.
    seekingalpha.com
  • R
    Rick
    Had a SCS implant from this company last yr, made it possible to participate in life again.
  • S
    Sektor
    nvta in pre market monday morning
  • B
    Bill mddb
    Medtronic (NYSE:MDT) has agreed to acquire all outstanding shares of spinal surgery device maker Medicrea (OTCQX:MRNTF) at €7.00/share, representing a 22% premium over yesterday's closing price.
    Medtronic (NYSE:MDT) has agreed to acquire all outstanding shares of spinal surgery device maker Medicrea (OTCQX:MRNTF) at €7.00/share, representing a 22% premium over yesterday's closing price.
    seekingalpha.com
  • S
    SdDavid
    What a piece if krap stock, negative return, year to date?🤔😅
  • b
    bills
    Thank you Motley Fool. $$$ for us.

    One quality stock that isn't among the most popular list on Robinhood is Medtronic (NYSE:MDT). Fewer than 12,000 Robinhood users are holding shares of the Dividend Aristocrat. Despite paying a dividend yield of 2.5% (more than the S&P 500 average of 2%) and raising its payouts for more than four decades in a row, the healthcare stock hasn't attracted much interest from Robinhood investors. But that makes the boring old dividend stock an attractive buy for income investors -- it's not volatile and not on retail investors' radars.
    With profits in nine straight quarters and Medtronic selling various medical products, it's a safe investment to hold for the long term. It's down 19% so far in 2020 while the S&P has fallen by a more modest 4%.
    But a lot of that bearishness can likely be attributed to COVID-19. Dealing with the pandemic has been a priority for hospitals and that's resulted in the deferral of many medical procedures, which has hampered Medtronic's sales. The Irish company released its fourth-quarter results on May 21, which showed sales were down 26% year over year. However, Medtronic was still able to post a profit of $646 million, showing a lot of resiliency during a very difficult time for the healthcare industry.
    The key takeaway from all this is that investors should avoid chasing stocks that are popular on Robinhood and instead do their own due diligence when deciding on which companies to invest in. Buying a stock because it's hot is an easy way to add a lot of volatility to your portfolio. And odds are that isn't going to be a great strategy as the economy is in a recession and the world is dealing with a pandemic -- which could suggest that another market crash may not be too far away.
    Now's a time to exercise caution and stick with safe stocks like Medtronic that can help get your portfolio through this adversity.
  • C
    ClarkKent
    possible break out at $ 96.00. end of week. then to $ 100 +.
  • L
    Len
    MDT was just mentioned on NBC news as being only one of 5 companies in the USA manufacturing ventilators. Only 7 more companies internationally.